newsfilter
← Latest News
GlobeNewswire·

The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

AVAILGVNLLYNVOVKTX
  • The global anti-aging market exceeded $85 billion in 2025 and is projected to reach $120 billion by 2030, with private longevity science investment doubling to $8.49 billion across 325 deals last year.
  • The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025, including the first formal class of "longevity therapeutics," while big pharma spent over $65 billion acquiring biotech companies through October 2025.
  • Avaí Bio, Inc. (OTCQB: AVAI) rebranded from Avant Technologies in February 2026 to focus on cellular therapies for diabetes and age-related disorders via its Klothonova joint venture with Austrianova for α-Klotho protein therapies.
  • Avaí Bio is advancing two parallel programs: a genetically modified cell line for a bio-artificial pancreas to treat type 1 and insulin-dependent type 2 diabetes, and the Klothonova venture developing α-Klotho therapies for Alzheimer's, cancer, and longevity.
  • Klothonova initiated Master Cell Bank production under GMP standards in March 2026 and plans to present new α-Klotho data at the Second Annual Klotho Conference in September 2026.
  • Peer companies including Eli Lilly, Novo Nordisk, Viking Therapeutics, and Longeveron reported significant clinical or commercial developments in Q1 2026, signaling a sector shift from concept to deployment.
  • Eli Lilly extended its market lead in February 2026 with oral GLP-1 programs outperforming rivals, while Novo Nordisk received FDA approval for a higher-dose Wegovy in March 2026 and reported pill superiority in April 2026.
  • Viking Therapeutics completed patient enrollment in its Phase 3 VANQUISH-2 trial for VK2735 in March 2026 and plans to launch two Phase 3 trials for its oral program in Q3 2026.
  • Longeveron published Phase 2b results in February 2026 showing laromestrocel improved physical condition in patients with age-related frailty, with top-line results for its HLHS trial expected in Q3 2026.
  • Demographic trends drive demand, with adults 60+ comprising 17% of the U.S. population but accounting for 37% of healthcare spending, and the global 60+ cohort projected to reach 1.4 billion by 2030.
  • Avaí Bio utilizes Austrianova's Cell-in-a-Box® encapsulation technology to protect genetically modified cells from immune rejection while allowing therapeutic payloads to diffuse.
  • The article discloses that Equity-Insider.com, a subsidiary of Market IQ Media Group, holds shares of Avaí Bio and received compensation for the distribution of this promotional content.